TCG Crossover Management, LLC
CIK 0001839948 · PALO ALTO, CA · Quarter end: 2026-06-30 · Filed on: 2026-08-14 · Open the SEC source ↗
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$4.16B
2026 Q2
Positions
54
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
57.4%
Est. Net Flow (Q)
—
2026 Q2
Top Holdings
ABVX
ABIVAX SA AMERICAN DEPOSITARY SHARES
19.2%
TNGX
TANGO THERAPEUTICS INC
6.8%
CGON
CG ONCOLOGY INC
6.3%
COGT
COGENT BIOSCIENCES INC
4.5%
IMVT
IMMUNOVANT INC
4.1%
SYRE
SPYRE THERAPEUTICS INC
4.1%
DNTH
DIANTHUS THERAPEUTICS INC
3.9%
MIRM
MIRUM PHARMACEUTICALS INC
3.0%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.